Biologists working on controversial, cutting-edge technology say they fear what will happen if recent advances come to the attention of President Donald Trump.
Trump hasn’t made any public comments about research involving stem cells, human embryos, or gene editing. But researchers live in fear of an incendiary tweet or a sudden announcement of policies that restrict research. They feel they are at risk because of how sensitive technologies have hurtled forward during Trump’s first 10 months in office.
Just this year, U.S. researchers demonstrated a working artificial womb, used CRISPR to correct a genetic defect in human embryos, took strides toward manufacturing synthetic embryos, and moved forward with an in vitro fertilization procedure that uses DNA from three biological parents.
“Mr. Trump has not paid attention to us. It would not be good if he paid attention to us,” Gerald Schatten, a stem-cell researcher at the University of Pittsburgh, told a gathering of 130 fertility experts from 30 countries at a conference at New York’s Plaza Hotel in October.
Researchers are concerned that any one of the new advances could prompt steps by the Trump administration to limit science, similar to President George W. Bush’s restrictions on federal funding for stem-cell research in 2001.
“There is precedent here,” says Gretchen Goldman, research director for the Center for Science and Democracy at the Union of Concerned Scientists, a nonprofit science advocacy group. “We’re hearing from folks that they’re aware how politically controversial their work is.”
Adding to scientists’ anxiety is that Trump’s views on the frontiers of biology are simply unknown. Of the president’s more than 30,000 tweets so far, none mention DNA, stem cells, or gene editing, according to the Trump Twitter Archive.
Meanwhile, Congress hasn’t held a hearing on such technology since June 2015.
“While President Trump doesn’t appear to have any strong beliefs on [these subjects], it’s clear that he’s composed a cabinet of individuals that may be less than thrilled about the prospects of such research,” says Ryan Hagemann, director of technology policy at the Niskanen Center, a libertarian think tank based in Washington, D.C.
The political atmosphere means even scientists who've made efforts to raise public awareness about new technology see the chance for trouble. Jennifer Doudna, one of the inventors of CRISPR, says she is worried that fast advances in gene-editing technology could backfire if they come to the attention of politicians in the wrong way.
“In the short term, my worst-case scenario is that somebody, somewhere, does something with CRISPR that is dangerous, or at least is perceived as dangerous or irresponsible, that leads to a big public backlash,” Doudna told a gathering of science journalists in San Francisco last month.
“Let’s say if tomorrow a CRISPR baby were to be announced—how would that be received in the current climate of the United States? I worry that this would ... cause a lot of people to call their government representatives and say, ‘What is this CRISPR? You need to shut that down.’”
Ten months into his presidency, President Trump has yet to choose a science advisor, the longest any modern president has taken to do so, notes the Washington Post.
In the absence of expert advice, the administration has acted in ways that many see as anti-science, including appointing Scott Pruitt, who questions man-made climate change, to lead the Environmental Protection Agency. Trump himself tweeted that global warming is “a hoax.”
More recently, the administration has taken steps to define embryos as human beings with legal rights—something that could curtail research on infertility, miscarriage, and the development of inherited diseases in human embryos.
Such language found its way into a draft strategic plan the Department of Health and Human Services released in October. A sentence saying the agency serves “Americans at every stage of life” was changed to read “Americans at every stage of life, beginning at conception.” And when congressional Republicans unveiled a 429-page tax bill on November 2, it stipulated that parents could set up a tax-advantaged college saving account for a “child in utero.”
Congresswoman Diana DeGette, a Democrat from Colorado, called the provision “a back-door attempt to establish personhood from the moment of conception.”
So far, biologists have largely been shielded from Trump’s attention. Although the president early on called for slashing the budget of the National Institutes of Health by $7.5 billion, that idea hasn’t gained any political support.
The president also held onto Francis Collins, a deft administrator named head of the NIH by former President Barack Obama and one of the few holdovers to have navigated the change of administration.
Even so, some biologists wonder if they should postpone important public discussions about controversial technology indefinitely, given the risk that Trump could weigh in.
One of those debates concerns the “14-day rule,” a guideline that says scientists doing embryo research shouldn’t grow human embryos in the lab for more than two weeks. In the U.S., it’s a self-imposed rule that scientists follow, but in several other countries, it’s legally binding. Given recent advances in editing embryos and growing organ-like structures in the lab, some scientists argue that it’s time to loosen the rule and let research go further.
During a meeting last month at the National Academies of Science in Washington, D.C., a panel of experts disagreed on whether the advisory body should broach the issue by carrying out a study and making recommendations.
Alta Charo, a professor of law and bioethics at the University of Wisconsin at Madison, said at the meeting that openly debating the rule could “invite some unwanted attention” from the Trump administration and state legislators. “My overriding concern is that this discussion and any action in this area is going to trigger state legislation,” she told members of the National Academies’ committee on technology, policy, and law.
Committee cochair David Baltimore, a world-renowned biologist at the California Institute of Technology, said he thought a study should move ahead, regardless of the political atmosphere.
“Doing the study is something that we shouldn’t be afraid of,” he said.
Bernard Lo, former director of the program of medical ethics at the University of California, San Francisco, acknowledged that the 14-day rule needs updating but agreed there is “less opportunity for common ground in the current political climate.”
“We’re in an Internet era of instant opinion,” he said.
Biotechnology and health
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
A biotech company says it put dopamine-making cells into people’s brains
The experiment to treat Parkinson’s is a critical early test of stem cells’ potential to tackle serious disease.
Tiny faux organs could crack the mystery of menstruation
Researchers are using organoids to unlock one of the human body’s most mysterious—and miraculous—processes.
After 25 years of hype, embryonic stem cells are still waiting for their moment
Research roadblocks and political debates have delayed progress—but scientists are inching closer to delivering a cure.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.